Relief Therapeutics Holding AG
RLFTD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | -0.05 | -0.02 |
| FCF Yield | -8.89% | -59.92% | -38.97% | -45.37% |
| EV / EBITDA | -1.31 | -0.17 | -0.99 | -2.09 |
| Quality | ||||
| ROIC | -34.28% | -138.51% | -27.01% | -14.35% |
| Gross Margin | 69.41% | 68.18% | 79.44% | -258.54% |
| Cash Conversion Ratio | 0.17 | 0.18 | 0.47 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.45% | 22.02% | – | – |
| Free Cash Flow Growth | 82.90% | 26.68% | 50.16% | -171.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.78 | 0.11 | 0.30 | 1.24 |
| Interest Coverage | -87.84 | -675.78 | -265.51 | -128.01 |
| Efficiency | ||||
| Inventory Turnover | 2.47 | 3.45 | 79.77 | 30.45 |
| Cash Conversion Cycle | 5.06 | 82.67 | 107.17 | 261.68 |